BioMedNewsBreaks

TuesdayJul 27, 2021 3:44 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Eyes Expanded Customer Base, Multiple Collaborations, Fulfillment of Researchers’ Needs

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that two of its four subsidiaries, Soluble Biotech and TumorGenesis, are expanding their services with the construction of new good manufacturing practices (“GMP”) laboratories. For Soluble Biotech, the GMP facility ramps up its formulation solutions and stability services so the company can rapidly provide clinical-trial-ready formulations to its customers. The lab will also be utilized to produce proprietary media used in its chromatography kits. A recent article reads, “Dr. Larry DeLucas, VP of Operations at Predictive Oncology, said he…

Continue Reading

TuesdayJul 27, 2021 11:42 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Manufacture of Synthetic Ibogaine Moves to Second Stage

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has begun the second stage of manufacturing pharmaceutical-grade ibogaine to be used in clinical research. According to the announcement, this stage will focus on assessing the quality of MINDCURE’s synthetic ibogaine when produced at scale to determine the timing and cost for commercial-scale manufacturing. The company intends to manufacture pharmaceutical-grade ibogaine to provide researchers with a consistent supply of sustainable, high-quality, reliable psychedelic substance. The company has already filed patent applications for two routes of chemical synthesis of ibogaine, with both…

Continue Reading

MondayJul 26, 2021 10:30 am

BioMedNewsBreaks – Avricore Health Inc.’s (TSX.V: AVCR) (OTCQB: AVCRF) HealthTab(TM) Adds ID Now(TM) Molecular Test Device to Abbott Distribution Agreement

Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) today announced the signing of the first amendment to its supplier distribution agreement between HealthTab(TM) Inc., a wholly owned subsidiary, and Abbott, a global health care company and diagnostics leader in Canada. According to the update, the agreement, first signed on May 31, 2021, allows HealthTab(TM) to distribute in Canada Abbott’s Afinion(TM) 2, as well as associated tests for diabetes and heart-disease screening in community pharmacies. This includes HbA1c testing, which lead to the subsequent signing of a master agreement with Shoppers Drug Mart to bring this new testing to select locations as an…

Continue Reading

FridayJul 23, 2021 11:13 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Poised as Key Innovative Leader at Forefront in Neurology Tech

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is a recognized leading innovative player in the brain monitoring space. The company continues to be at the forefront of what is next in neurology technology. In a Tech Times feature, Brain Scientific’s Marketing Director Irina Nazarova outlined key brain monitoring trends to watch in 2021, including the fact that brain monitoring is becoming as popular and widespread as monitoring pulse or heart rate. Several potential applications have swelled, and EEG monitoring is no longer a preserve of clinicians and expert neuroscientific researchers. A recent article…

Continue Reading

FridayJul 23, 2021 10:53 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Looking to Unlock Additional Value with Russell 2000 Index Inclusion

CNS Pharmaceuticals (NASDAQ: CNSP), a pharmaceutical company enthusiastically pursuing enrollment of about 243 brain cancer patients in a clinical trial designed to analyze the efficacy and safety of its lead drug candidate, was selected to be added to the Russell 2000 Index effective June 25. A subset of the Russell 3000 Index, the Russell 2000 Index is a measure of the performance of the small-cap segment of the U.S. equity market. Per CNS Pharmaceuticals CEO John Climaco, quoted in a recent article, the company was pleased to meet this noteworthy milestone. He said, “As our team continues to drive our…

Continue Reading

TuesdayJul 20, 2021 11:04 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Definitive Agreement to Acquire 3a-Diagnostics

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, has signed a definitive agreement to acquire its exclusive diagnostics development partner 3a-diagnostics GmbH, Frickenhausen, Germany. Per the terms of the definitive agreement, XPhyto will acquire all outstanding shares of 3a for EUR 400,000, to be paid immediately, and EUR 3.5 million, to be paid on closing, which is anticipated to take place on or around October 31, 2021. This acquisition will create considerable commercial development and manufacturing opportunities for XPhyto, in addition to providing improved margins on its diagnostic products. “We have collaborated closely with the 3a-diagnostics…

Continue Reading

MondayJul 19, 2021 12:19 pm

BioMedNewsBreaks – Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Announces Successful Beta Testing of HealthTab(TM)

Avricore Health  (TSX.V: AVCR) (OTCQB: AVCRF) today announced that patient testing has begun on the first deployment of the new HealthTab(TM)-integrated Afinion 2(TM) analyzers in the initial Shoppers Drug Mart(R) pharmacy location. This move is part of the company’s previously announced effort to screen for diabetes and cardiovascular disease, demonstrating strong demand, smooth workflow and reliable system operations. To prepare for the full public launch, a first store was selected to receive the system to begin beta-testing HealthTab(TM)’s systems, including the first patient tests. HealthTab(TM) and the instruments are performing well, demonstrating that the first installation of HealthTab(TM) with the Afinion…

Continue Reading

MondayJul 19, 2021 10:39 am

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Announces Collaboration with University of Milan for ‘Precedent-Setting Experiment’

RYAH Group (CSE: RYAH) today announced its entry into a strategic partnership with the University of Milan, a leading education and research institution, to develop and formalize universal milliliter (“ml”) to milligram (“mg”) conversion standards in dry herb cannabis inhalation therapies for its RYAH Smart Dry Herb Inhalers. According to the update, the RYAH Smart Dry Herb Inhaler is an IoT-powered dry herb inhaler with an integrated volumetric airflow sensor that gives consumers the ability to track and control exactly how much they inhale. “Our collaboration with the University of Milan is expected to afford us an incredible opportunity to,…

Continue Reading

FridayJul 16, 2021 1:48 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Stands Distinct in Precision Medicine

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is leveraging its unique, historical database of the drug responses of over 150,000 patient tumors to build data-driven predictive models of tumor drug response. These models will provide actionable insights critical to both new drug development and individualizing patient treatment. “While others must wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine,” a recent article reads. “Predictive Oncology presently has the clinical information, including tumor drug response data and…

Continue Reading

FridayJul 16, 2021 11:51 am

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Brings Powerful Capabilities to Modern Clinical Trials

RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics. These provide next-generation capabilities that allow for more control of variables within a clinical setting, which is especially significant in modern cannabis clinical trials. While historical emphasis has largely been centered on potential harmful effects, today’s research teams are exploring the use of cannabis to address a wide range of chronic conditions, while it holds significant potential for pain relief. The future of cannabis study with the addition of dose-measuring devises looks promising, and RYAH is front-and-center on the…

Continue Reading